These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16609025)

  • 1. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
    Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
    Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
    Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
    Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
    J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
    Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
    Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
    Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
    Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
    Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
    Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group.
    Shiozawa E; Takimoto M; Makino R; Adachi D; Saito B; Yamochi-Onizuka T; Yamochi T; Shimozuma J; Maeda T; Kohno Y; Kawakami K; Nakamaki T; Tomoyasu S; Shiokawa A; Ota H
    Leuk Res; 2006 Jul; 30(7):859-67. PubMed ID: 16406514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.
    Filipits M; Jaeger U; Pohl G; Stranzl T; Simonitsch I; Kaider A; Skrabs C; Pirker R
    Clin Cancer Res; 2002 Mar; 8(3):729-33. PubMed ID: 11895902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
    Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
    Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
    Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
    Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
    Sakane-Ishikawa E; Nakatsuka S; Tomita Y; Fujita S; Nakamichi I; Takakuwa T; Sugiyama H; Fukuhara S; Hino M; Kanamaru A; Soma T; Tsukaguchi M; Igarashi K; Kanakura Y; Aozasa K;
    J Clin Oncol; 2005 Nov; 23(31):8012-7. PubMed ID: 16258099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
    Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
    Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Klapper W; Stoecklein H; Zeynalova S; Ott G; Kosari F; Rosenwald A; Loeffler M; Trümper L; Pfreundschuh M; Siebert R;
    Leukemia; 2008 Dec; 22(12):2226-9. PubMed ID: 18754028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.